Castle Biosciences Presents New Data Highlighting Use Of DecisionDx-Melanoma To Identify Early-Stage Melanoma Patients At High Risk Of Metastasis To The Central Nervous System To Prompt Use Of Imaging Surveillance At 2024 ASCO Annual Meeting

5/30/24 5:01:03 PM ET

Medical Specialities

Health Care

Get the next $CSTL alert in real time by email

Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2)

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31-June 4, 2024, in Chicago.

Get the next $CSTL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CSTL

Date	Price Target	Rating	Analyst
12/14/2023	$25.00	Buy	Guggenheim
1/5/2023	$54.00	Sector Outperform	Scotiabank
1/7/2022	$59.00	Overweight	Stephens & Co.
11/9/2021	$85.00 → $75.00	Outperform	SVB Leerink
7/14/2021	$80.00 → $85.00	Outperform	SVB Leerink

More analyst ratings

Castle Biosciences Reports Third Quarter 2024 Results
Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024. "We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedication of our team," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
11/4/24 4:05:00 PM ET
$CSTL
Medical Specialities
Health Care
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/435529710, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.as
10/14/24 7:00:00 AM ET
$CSTL
Medical Specialities
Health Care
Castle Biosciences Reports Second Quarter 2024 Results
Q2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2024. "We achieved another quarter of exceptional performance, thanks to the hard work of our talented team and strength of our innovative test portfolio," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
8/5/24 4:05:00 PM ET
$CSTL
Medical Specialities
Health Care

$CSTL
Leadership Updates

Live Leadership Updates

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit
4/30/24 4:30:00 PM ET
$CSTL
Medical Specialities
Health Care
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors
-Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in
10/23/23 8:00:00 AM ET
$CSTL
$EQ
$ICPT
Medical Specialities
Health Care
Biotechnology: Pharmaceutical Preparations
AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors
SAN DIEGO, May 26, 2021 /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful
5/26/21 12:42:00 PM ET
$CSTL
Medical Specialities
Health Care

$CSTL
Market Insights

Live Market Insights

Top 5 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Cassava Sciences Inc (NASDAQ:SAVA) On July 1, Cassava Sciences engaged the U.S. Department of Justice (DOJ) and the U.S. Secu
7/8/24 8:40:10 AM ET
$CSTL
$NRC
$OMI
$PCRX
Medical Specialities
Health Care
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Pharmaceutical Preparations
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb
7/5/24 12:59:40 PM ET
$ANVS
$APLD
$ARM
$BTDR
Biotechnology: Pharmaceutical Preparations
Health Care
Finance: Consumer Services
Finance
Baird Maintains Outperform on Castle Biosciences, Maintains $34 Price Target
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and maintains $34 price target.
7/5/24 12:53:18 PM ET
$CSTL
Medical Specialities
Health Care

$CSTL
Press Releases

Fastest customizable press release news feed in the world

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available following the conclusion of the live broadcast. About Castle Biosciences Castle Biosciences (NASDAQ:CSTL) is a leading diagnostics company improving healt
11/20/24 7:00:00 AM ET
$CSTL
Medical Specialities
Health Care
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Top Workplace for 2024 by the Houston Chronicle. This is the fourth consecutive year the Company has been ranked among the Houston metro area's top workplaces. Castle also earned three Culture Excellence awards in the areas of Employee Appreciation, Employee Well-Being and Professional Development. "Achieving a Houston Top Workplace honor for the f
11/19/24 7:00:00 AM ET
$CSTL
Medical Specialities
Health Care
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology (ASDP) 61st Annual Meeting, being held Nov. 7-10, in Chicago. "At Castle, we focus strongly on continued evidence development to demonstrate where our tests might be able to add value to clinical decision-making," said Rebecca Critchley-Thorne, Ph.D., vice president of research and development at Castle Biosciences. "Our data to be presented at ASDP support the ability of our tests to provide accurate risk-stratification i
11/8/24 7:00:00 AM ET
$CSTL
Medical Specialities
Health Care

Castle Biosciences Presents New Data Highlighting Use Of DecisionDx-Melanoma To Identify Early-Stage Melanoma Patients At High Risk Of Metastasis To The Central Nervous System To Prompt Use Of Imaging Surveillance At 2024 ASCO Annual Meeting

Chat with this insight

Recent Analyst Ratings for $CSTL

$CSTL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

$CSTL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Castle Biosciences with a new price target

Scotiabank initiated coverage on Castle Biosciences with a new price target

Stephens & Co. initiated coverage on Castle Biosciences with a new price target

$CSTL SEC Filings

SEC Form 144 filed by Castle Biosciences Inc.

SEC Form 10-Q filed by Castle Biosciences Inc.

Castle Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$CSTL Financials

Live finance-specific insights

$CSTL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Castle Biosciences Reports Third Quarter 2024 Results

Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024

Castle Biosciences Reports Second Quarter 2024 Results

Chief Financial Officer Stokes Frank sold $207,217 worth of shares (6,923 units at $29.93), decreasing direct ownership by 18% to 30,823 units (SEC Form 4)

Pres. & Chief Exec. Officer Maetzold Derek J sold $175,087 worth of shares (5,127 units at $34.15), decreasing direct ownership by 2% to 87,720 units (SEC Form 4)

Chief Commercial Officer Juvenal Tobin W exercised 3,507 shares at a strike of $3.38 and sold $124,709 worth of shares (3,507 units at $35.56) (SEC Form 4)

$CSTL Leadership Updates

Live Leadership Updates

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

$CSTL Market Insights

Live Market Insights

Top 5 Health Care Stocks That May Explode In July

Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Baird Maintains Outperform on Castle Biosciences, Maintains $34 Price Target

$CSTL Press Releases

Fastest customizable press release news feed in the world

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Recent Analyst Ratings for
$CSTL

$CSTL
Large Ownership Changes

$CSTL
Analyst Ratings

$CSTL
SEC Filings

$CSTL
Financials

$CSTL
Insider Trading

$CSTL
Leadership Updates

$CSTL
Market Insights

$CSTL
Press Releases